April 16, 2025 Nvidia’s $5.5B AI Chip Crunch and ASML’s Tariff Jitters
Apple: Dividend Growth Ahead, But a Near-Term Slide Likely
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
Novavax (NVAX) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: April 29, 2025 (21:37)
Sector: HealthcareThe share price of Novavax, Inc. (NVAX) now
Analysts predictions
Full report|
This Week
|
Neutral | Opinions: Na |
|
Previous Week
|
Neutral | Opinions: Na |
|
Two Weeks Ago
|
Neutral | Opinions: 1 |
|
Three Weeks Ago
|
Neutral | Opinions: Na |
Are you interested in Novavax, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Novavax stock price in 2025, 2026, 2027. How much will one Novavax share be worth in 2025 - 2027?
When should I take profit in Novavax stock? When should I record a loss on Novavax stock? What are analysts' forecasts for Novavax stock? What is the future of Novavax stock? We forecast Novavax stock performance using neural networks based on historical data on Novavax stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Novavax stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2025, 2026, 2027, and ) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Novavax shares. This happens once a day.
Historical and forecast chart of Novavax stock
The chart below shows the historical price of Novavax stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Novavax stock price can be found in the table below.
Long-term forecasts by years.
Novavax, Inc. Analysts predictions review
Novavax (NVAX) faces significant headwinds, including regulatory delays, weak COVID-19 vaccine demand, and a narrow product pipeline. Despite short-term cost-cutting measures improving its cash position, dependency on pandemic-era products and lack of diversification limit near-term growth prospects. Heightened competition and execution risks further compound challenges to revenue stability. Investors should remain cautious as ongoing struggles and limited catalysts weigh heavily on sentiment, maintaining a bearish outlook.
Navigating Novavax: Balancing Regulatory Risks and Upside Potential
Regulatory challenges remain a key driver of uncertainty for Novavax (NVAX). The author identifies delays in regulatory approvals for its vaccine products as a significant headwind. Such delays not only impede revenue generation but also create a perception of operational inefficiency, weighing heavily on investor sentiment.
The company’s undervalued stock price presents a potential opportunity for high-risk, high-reward investors. According to the author, NVAX's beaten-down valuation reflects the market's skepticism but also implies scope for sharp recoveries should regulatory or operational hurdles be successfully mitigated.
Pipeline and Commercialization Risks Continue to Overshadow Growth
Novavax's reliance on a narrow product pipeline exacerbates volatility in stock performance. The author highlights that setbacks in clinical trials or commercialization of its flagship vaccine could disproportionately affect the company’s financial stability and valuation.
Additionally, increased competition in the vaccine industry intensifies pressure on Novavax to execute flawlessly. Larger players with stronger financial resources pose challenges to Novavax's market share, pushing the need for successful innovation and differentiation.
Novavax's Q4 Results and Downsizing Strategy: A Cautious Outlook for Investors
Novavax's Q4 earnings report revealed a mix of challenges, particularly driven by weaker-than-expected revenue and a broader decline in COVID-19 vaccine demand. These factors underscore their ongoing struggle to stabilize performance in a post-pandemic landscape, raising concerns about near-term earnings sustainability and market positioning.
Of note, the company's cost-cutting and downsizing strategy points to an attempt at operational efficiency. However, the downsizing plan may also signal a lack of confidence in its long-term revenue growth prospects, potentially deterring growth-focused investors.
Near-Term Outlook and Market Implications
The company’s ongoing cash burn and dependency on its COVID-19 vaccine portfolio, amid dwindling demand, significantly weigh on its stock outlook. Additionally, the lack of diversification in its product pipeline may heighten investor concerns about its ability to generate consistent revenue streams in the future.
The author's analysis suggests a cautious stance, as these issues collectively could exert sustained downward pressure on Novavax stock. The immediate-term sentiment for the stock leans heavily bearish, unless there are significant catalysts to rejuvenate investor confidence.
Novavax Navigates Challenges with Improved Prospects Amid Strategic Shifts
Novavax has demonstrated progress in monetizing its COVID-19 vaccine portfolio while facing ongoing operational hurdles. The author highlights that the company’s efforts to capitalize on existing product opportunities have led to a stronger near-term cash position, which is crucial for navigating its liquidity challenges and improving investor sentiment.
Operational inefficiencies and the heavy reliance on COVID-related revenues remain critical pressure points. As pointed out, strategic cost-cutting measures to streamline operations are likely to provide some relief, yet the sustainability of positive cash flows hinges on the company's ability to diversify its revenue streams and reduce dependency on pandemic-era products.
Key Drivers of NVAX Stock Movement
The pipeline diversification strategy was underscored as a potential catalyst for future growth. Focus on non-pandemic vaccine developments could provide long-term value, but these projects are still in early stages and will require significant investment, making near-term revenue growth uncertain.
The author also notes regulatory and competitive risks that could weigh on Novavax's stock performance. Given the competitive vaccine landscape, execution remains critical, with shareholder confidence closely tied to the company's ability to deliver on its strategic commitments while navigating potential regulatory hurdles.
Novavax's upcoming Q3 earnings report arrives at a critical juncture as the company navigates a volatile operating environment and financial pressures. Among the factors influencing NVAX's near-term outlook, the company's reliance on its COVID-19 vaccine portfolio is a significant area of concern. This product concentration poses a risk given slowing demand for pandemic-related vaccines and increasing competition within the market.
Another key factor discussed is Novavax's precarious financial position, characterized by high cash burn and the need to secure additional funding. The analyst underscores how these liquidity challenges could impede long-term operational viability, potentially leading to eased investor confidence and weaker stock momentum.
Strategic Priorities and Market Position
The author's analysis also highlights management's recent pivot toward cost-cutting measures and renewed focus on a streamlined product pipeline. While this signifies a pragmatic approach to stabilizing operations, the associated delays in innovation might temper the stock's performance prospects over the near term.
Finally, external market dynamics, including regulatory headwinds and macroeconomic volatility, remain critical obstacles. These factors introduce uncertainties that could extend the company's path to profitability, further pressuring the stock in the short-to-medium term.
Novavax is grappling with a critical issue of limited sustainable revenue growth. The company's top-line performance appears highly dependent on pandemic-driven vaccine demand, which has shown signs of significant deceleration over recent quarters, raising questions about its ability to diversify and stabilize its revenue base.
Impact of Market Competition and Leadership Execution
Competitors with robust pipelines and established global distribution networks are pressuring Novavax's market share. This intensifies the importance of strategic product differentiation and cost management, which the author suggests remain areas of concern for investors monitoring this stock.
Additionally, leadership's ability to navigate operational inefficiencies and execute on key strategic initiatives has been inconsistent. The perceived lack of urgency in adapting to a post-pandemic market landscape compounds investor hesitancy, particularly as the company faces heightened cash constraints amidst tepid revenue growth.
Finally, if Novavax fails to establish reliable revenue channels outside its COVID-19 vaccine portfolio, the stock faces downward pressure. Long-term sustainability hinges on resolving structural issues and delivering on pipeline diversification.
NVAX's recent financial performance emphasizes its ongoing challenges in achieving profitability. A persistent gap between revenue growth and operating expenses signals the need for improved cost management, a factor likely to sustain downward pressure on the stock price unless notable efficiency gains are realized.
The company’s pipeline developments hold promise but are overshadowed by competitive pressures and slower-than-expected commercialization timelines. According to the author, delays in product rollouts might diminish near-term revenue expectations, weighing on investor sentiment.
Market Position and Valuation in Focus
Heightened competition in the biotechnology sector further challenges NVAX’s ability to capture significant market share. The author notes that maintaining relevance among larger, more resourceful peers could hinder NVAX’s ability to translate innovation into tangible financial results.
Overall, NVAX's share performance remains tied to resolving operational inefficiencies and delivering measurable progress in its product portfolio. Until these uncertainties are addressed, the stock’s trajectory appears cautiously constrained.
Novavex, Inc. Together with its subsidiary Novavax AB, a late-stage biotechnology company, it discovers, develops and commercializes vaccines to prevent serious infectious diseases. The company’s leading vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate, which is in stage III clinical trials to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in phase III clinical trials for the treatment of seasonal influenza in the elderly. Its leading adjuvant is Matrix-M, which is used to enable the vaccine to enhance the amplitude of the immune response and qualitatively change it, and to allow the immune system to attack microorganisms, and also to allow immunization with much smaller doses of antigen. The company is also developing the RSV F vaccine for the elderly (60 years and older), which is in phase II clinical trials, as well as for healthy children aged six months to five years, who are in phase I clinical trials. In addition, it is developing candidate nanoparticle vaccines for clinical trials against the Ebola virus, which is in clinical trials stage I; and a combined respiratory vaccine to protect against influenza and RSV. In addition, the company is developing a COVID-19 vaccine against the pneumonia-like coronavirus, which is in the preclinical stage. Novavex, Inc. the company was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Novavax daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May 01 | 7.48 | 7.18 | 7.77 | 8.15 |
| May 02 | 7.56 | 7.30 | 7.87 | 7.83 |
| May 03 | 7.13 | 6.72 | 7.57 | 12.80 |
| May 04 | 6.50 | 6.09 | 6.92 | 13.64 |
| May 05 | 6.73 | 6.45 | 7.15 | 10.90 |
| May 06 | 6.48 | 6.23 | 6.60 | 5.90 |
| May 07 | 6.52 | 6.28 | 6.81 | 8.41 |
| May 08 | 6.73 | 6.37 | 7.07 | 10.93 |
| May 09 | 7.11 | 6.97 | 7.60 | 9.09 |
| May 10 | 7.19 | 6.75 | 7.36 | 9.11 |
| May 11 | 7.34 | 7.19 | 7.81 | 8.55 |
| May 12 | 7.61 | 7.12 | 7.80 | 9.53 |
| May 13 | 7.89 | 7.52 | 8.28 | 10.10 |
| May 14 | 7.63 | 7.46 | 8.08 | 8.29 |
| May 15 | 7.63 | 7.30 | 7.94 | 8.85 |
| May 16 | 7.78 | 7.24 | 8.06 | 11.30 |
| May 17 | 7.76 | 7.27 | 7.91 | 8.73 |
| May 18 | 7.53 | 7.04 | 7.97 | 13.17 |
| May 19 | 6.90 | 6.41 | 7.34 | 14.63 |
| May 20 | 6.66 | 6.22 | 6.95 | 11.66 |
| May 21 | 6.62 | 6.18 | 6.89 | 11.57 |
| May 22 | 6.25 | 5.97 | 6.46 | 8.20 |
| May 23 | 6.48 | 6.02 | 6.91 | 14.73 |
| May 24 | 7.05 | 6.73 | 7.25 | 7.74 |
| May 25 | 7.53 | 7.28 | 8.03 | 10.33 |
| May 26 | 7.91 | 7.76 | 8.47 | 9.17 |
| May 27 | 8.24 | 7.68 | 8.57 | 11.59 |
| May 28 | 8.49 | 8.16 | 8.87 | 8.72 |
| May 29 | 8.37 | 7.81 | 8.63 | 10.52 |
| May 30 | 8.61 | 8.27 | 8.85 | 7.03 |
Novavax Daily Price Targets
Novavax Stock Forecast 05-01-2025.
Forecast target price for 05-01-2025: $7.48.
Positive dynamics for Novavax shares will prevail with possible volatility of 7.538%.
Pessimistic target level: 7.18
Optimistic target level: 7.77
Novavax Stock Forecast 05-02-2025.
Forecast target price for 05-02-2025: $7.56.
Positive dynamics for Novavax shares will prevail with possible volatility of 7.259%.
Pessimistic target level: 7.30
Optimistic target level: 7.87
Novavax Stock Forecast 05-03-2025.
Forecast target price for 05-03-2025: $7.13.
Negative dynamics for Novavax shares will prevail with possible volatility of 11.345%.
Pessimistic target level: 6.72
Optimistic target level: 7.57
Novavax Stock Forecast 05-04-2025.
Forecast target price for 05-04-2025: $6.50.
Negative dynamics for Novavax shares will prevail with possible volatility of 12.002%.
Pessimistic target level: 6.09
Optimistic target level: 6.92
Novavax Stock Forecast 05-05-2025.
Forecast target price for 05-05-2025: $6.73.
Positive dynamics for Novavax shares will prevail with possible volatility of 9.830%.
Pessimistic target level: 6.45
Optimistic target level: 7.15
Novavax Stock Forecast 05-06-2025.
Forecast target price for 05-06-2025: $6.48.
Negative dynamics for Novavax shares will prevail with possible volatility of 5.570%.
Pessimistic target level: 6.23
Optimistic target level: 6.60
NVAX (NVAX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| May. | 7.81 | 6.03 | 8.68 | 30.51 |
| Jun. | 9.78 | 7.55 | 10.63 | 28.98 |
| Jul. | 9.54 | 7.25 | 10.95 | 33.74 |
| Aug. | 9.29 | 7.06 | 10.04 | 29.70 |
| Sep. | 9.90 | 8.21 | 11.77 | 30.28 |
| Oct. | 8.83 | 7.80 | 9.44 | 17.40 |
| Nov. | 10.29 | 9.55 | 12.32 | 22.54 |
| Dec. | 11.21 | 9.43 | 12.79 | 26.29 |
Novavax forecast for this year
Novavax Stock Prediction for May 2025
An uptrend is forecast for this month with an optimal target price of $7.81057. Pessimistic: $6.03. Optimistic: $8.68
Novavax Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $9.77883. Pessimistic: $7.55. Optimistic: $10.63
Novavax Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $9.54414. Pessimistic: $7.25. Optimistic: $10.95
Novavax Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $9.28645. Pessimistic: $7.06. Optimistic: $10.04
Novavax Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $9.89936. Pessimistic: $8.21. Optimistic: $11.77
Novavax Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $8.83022. Pessimistic: $7.80. Optimistic: $9.44
Novavax Stock Prediction for Nov 2025
An uptrend is forecast for this month with an optimal target price of $10.2872. Pessimistic: $9.55. Optimistic: $12.32
Novavax Stock Prediction for Dec 2025
An uptrend is forecast for this month with an optimal target price of $11.2131. Pessimistic: $9.43. Optimistic: $12.79
Novavax (NVAX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 10.81 | 9.48 | 11.88 | 20.20 |
| Feb | 8.83 | 7.61 | 10.00 | 23.85 |
| Mar | 7.51 | 6.18 | 8.61 | 28.25 |
| Apr | 7.93 | 6.93 | 9.72 | 28.65 |
| May | 8.86 | 8.12 | 9.39 | 13.58 |
| Jun | 9.61 | 8.68 | 11.62 | 25.29 |
| Jul | 9.26 | 7.40 | 10.98 | 32.63 |
| Aug | 9.26 | 7.65 | 10.37 | 26.25 |
| Sep | 9.48 | 7.38 | 10.54 | 29.97 |
| Oct | 11.16 | 8.78 | 13.00 | 32.45 |
| Nov | 10.22 | 8.54 | 12.07 | 29.24 |
| Dec | 10.01 | 8.15 | 11.78 | 30.84 |
Novavax (NVAX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 7.76 | 5.90 | 8.57 | 31.22 |
| Feb | 7.59 | 5.86 | 9.39 | 37.59 |
| Mar | 7.64 | 6.43 | 8.99 | 28.55 |
| Apr | 9.82 | 7.46 | 11.79 | 36.72 |
| May | 8.58 | 7.78 | 9.38 | 17.02 |
| Jun | 9.76 | 8.01 | 10.82 | 25.99 |
| Jul | 9.50 | 8.13 | 10.87 | 25.17 |
| Aug | 8.25 | 7.06 | 9.93 | 28.90 |
| Sep | 6.37 | 5.24 | 7.72 | 32.15 |
| Oct | 5.62 | 4.73 | 6.68 | 29.27 |
| Nov | 5.45 | 5.08 | 6.24 | 18.62 |
| Dec | 5.88 | 4.63 | 6.46 | 28.39 |
Novavax information and performance
20 FIRSTFIELD ROAD, GAITHERSBURG, MD, US
Market capitalization of the Novavax, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of NVAX shares in the company outstanding by the market price of one share.
EBITDA of Novavax is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Novavax (NVAX) stock dividend
Novavax last paid dividends on 01/01/1970. The next scheduled payment will be on 05/10/2019. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Novavax Stock)
Should I Buy Novavax Shares in 2025 year?
Does Novavax pay dividends?
Which economic sector do Novavax's shares belong to?
Which other securities belong to the same sector as Novavax's shares?
